FY2024 EPS Estimates for Trevi Therapeutics, Inc. (NASDAQ:TRVI) Cut by Leerink Partnrs

Trevi Therapeutics, Inc. (NASDAQ:TRVI) – Equities researchers at Leerink Partnrs decreased their FY2024 earnings per share estimates for shares of Trevi Therapeutics in a report released on Wednesday, May 8th. Leerink Partnrs analyst T. Smith now forecasts that the company will post earnings of ($0.46) per share for the year, down from their previous forecast of ($0.45). The consensus estimate for Trevi Therapeutics’ current full-year earnings is ($0.39) per share. Leerink Partnrs also issued estimates for Trevi Therapeutics’ Q4 2024 earnings at ($0.12) EPS, FY2025 earnings at ($0.62) EPS, FY2026 earnings at ($0.88) EPS, FY2027 earnings at ($1.12) EPS and FY2028 earnings at ($0.69) EPS.

Trevi Therapeutics (NASDAQ:TRVI) last posted its quarterly earnings results on Wednesday, March 20th. The company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.02.

A number of other brokerages have also weighed in on TRVI. Needham & Company LLC reissued a “buy” rating and issued a $8.00 target price on shares of Trevi Therapeutics in a research report on Wednesday. Oppenheimer restated an “outperform” rating and issued a $9.00 price target on shares of Trevi Therapeutics in a research note on Thursday, March 21st.

Trevi Therapeutics Trading Up 10.6 %

Shares of TRVI opened at $2.92 on Friday. Trevi Therapeutics has a 12 month low of $0.97 and a 12 month high of $4.00. The business’s fifty day simple moving average is $3.03 and its two-hundred day simple moving average is $2.07. The company has a market cap of $205.66 million, a price-to-earnings ratio of -10.07 and a beta of 0.91.

Institutional Trading of Trevi Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Frazier Life Sciences Management L.P. increased its stake in shares of Trevi Therapeutics by 7.3% in the fourth quarter. Frazier Life Sciences Management L.P. now owns 7,381,090 shares of the company’s stock worth $9,891,000 after purchasing an additional 500,000 shares in the last quarter. Opaleye Management Inc. increased its stake in Trevi Therapeutics by 48.6% in the 4th quarter. Opaleye Management Inc. now owns 2,535,000 shares of the company’s stock worth $3,397,000 after buying an additional 829,100 shares in the last quarter. Silverarc Capital Management LLC raised its holdings in Trevi Therapeutics by 4.7% during the third quarter. Silverarc Capital Management LLC now owns 927,415 shares of the company’s stock valued at $2,022,000 after acquiring an additional 41,491 shares during the period. SG Americas Securities LLC lifted its position in shares of Trevi Therapeutics by 401.4% in the fourth quarter. SG Americas Securities LLC now owns 98,253 shares of the company’s stock valued at $132,000 after acquiring an additional 78,656 shares in the last quarter. Finally, Oppenheimer & Co. Inc. bought a new position in shares of Trevi Therapeutics in the first quarter worth about $208,000. Hedge funds and other institutional investors own 95.76% of the company’s stock.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.